CANNAFX
Live / Registered — Registered — Sections 8 & 15 accepted and acknowledged (as of 12 Jun 2024)
What this means for you
Registered since 26 Dec 2017. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 26 Dec 2027: the §8 & §9 renewal).
Record
- Serial number
- 86209586
- Registration number
- 5365218
- Mark type
- Word mark
- Filed
- 03 Mar 2014
- Published for opposition
- 07 Jul 2015
- Registered
- 26 Dec 2017
- Next maintenance filing
- §8 & §9 renewal, due by 26 Dec 2027 (grace period to 26 Jun 2028)
- Attorney of record
- James David Johnson
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and dietary supplements for the treatment of pain, neuropathic pain, cancer pain, multiple sclerosis, spinal cord injury, bladder dysfunction, peripheral neuropathy, spasticity, oncology, cancer symptoms, psychiatric illnesses, neurodegenerative diseases and metabolic disorders derived from plant extracts for therapeutical purposes, excluding cannabis and cannabidiol
Owner
- Boston Research & Development, LLC, Norwood, MA, US
- Boston Research & Development, LLC, Norwood, MA, US
- Boston Research & Development, LLC, Norwood, MA, US
Prosecution history
- 12 Jun 2024 — NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED
- 12 Jun 2024 — REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
- 12 Jun 2024 — CASE ASSIGNED TO POST REGISTRATION PARALEGAL
- 07 Dec 2023 — TEAS SECTION 8 & 15 RECEIVED
- 26 Dec 2022 — COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
- 26 Dec 2017 — REGISTERED-PRINCIPAL REGISTER
- 23 Nov 2017 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 22 Nov 2017 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 06 Nov 2017 — EXAMINER'S AMENDMENT ENTERED
- 03 Nov 2017 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 03 Nov 2017 — EXAMINERS AMENDMENT E-MAILED
- 03 Nov 2017 — SU-EXAMINER'S AMENDMENT WRITTEN
- 29 Jun 2017 — NOTIFICATION OF FINAL REFUSAL EMAILED
- 29 Jun 2017 — FINAL REFUSAL E-MAILED
- 29 Jun 2017 — SU - FINAL REFUSAL - WRITTEN